Xiaoyang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoyang Liu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Luchen Yang
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China
3 shared publications- Qiang Dong
Department of Urology, West China Hospital, Sichuan University, Chengdu, China
3 shared publications Pan Song
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China
2 shared publicationsShengzhuo Liu
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China
2 shared publications- Xianding Wang
Department of Urology and Andrology Lab, West China Hospital, Sichuan University, Chengdu, China
2 shared publications Xin Yan
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Plasma Metabolomic Signatures Linked to Healthy Lifestyle and Risk of Benign Prostatic Hyperplasia
The aim of this study was to identify and validate a plasma metabolomic signature associated with healthy lifestyle and to examine their relationship with the risk of incident benign prostatic hyperplasia (BPH). From the UK Biobank, 89,388 male participants without baseline BPH were analyzed. Healthy lifestyle scores were calculated based on smoking status, alcohol consumption, physical activity, and sleep duration. Nuclear magnetic resonance-based metabolomics profiling was conducted on ethylenediaminetetraacetic plasma samples, measuring 251 metabolic biomarkers. An elastic net regression developed a metabolic signature representing a healthy lifestyle. Cox proportional hazard models assessed the associations between lifestyle, metabolic signature, and BPH risk, adjusting for confounders. Mediation analysis explored the metabolic signature's role in the lifestyle-BPH risk relationship. Results showed that higher healthy lifestyle scores correlated with reduced BPH risk, with a hazard ratio (HR) of 0.94 per one-point increase (95% confidence interval [CI]: 0.92 to 0.96). A metabolic signature of 83 metabolites was identified, significantly linked to healthier lifestyles and independently associated with lower BPH risk (HR=0.78, 95% CI: 0.72 to 0.83). Mediation analysis indicated that 19.7% (95% CI: 13.7% to 29.6%) of the lifestyle-BPH risk association was mediated by this signature, mainly through lipoprotein particles, cholesteryl esters in high-density lipoprotein, and phosphatidylcholines. In conclusion, healthy-lifestyle related metabolites were associated with a reduced risk of BPH. The findings highlight the potential of using metabolic signatures as biomarkers for personalized health strategies to reduce BPH incidence. Future research should aim to validate these results across diverse populations and investigate the long-term dynamics of lifestyle-induced metabolic changes.
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Open AccessPlasma Metabolomic Signatures Linked to Healthy Lifestyle and Risk of Benign Prostatic Hyperplasia
The aim of this study was to identify and validate a plasma metabolomic signature associated with healthy lifestyle and to examine their relationship with the risk of incident benign prostatic hyperplasia (BPH). From the UK Biobank, 89,388 male participants without baseline BPH were analyzed. Healthy lifestyle scores were calculated based on smoking status, alcohol consumption, physical activity, and sleep duration. Nuclear magnetic resonance-based metabolomics profiling was conducted on ethylenediaminetetraacetic plasma samples, measuring 251 metabolic biomarkers. An elastic net regression developed a metabolic signature representing a healthy lifestyle. Cox proportional hazard models assessed the associations between lifestyle, metabolic signature, and BPH risk, adjusting for confounders. Mediation analysis explored the metabolic signature's role in the lifestyle-BPH risk relationship. Results showed that higher healthy lifestyle scores correlated with reduced BPH risk, with a hazard ratio (HR) of 0.94 per one-point increase (95% confidence interval [CI]: 0.92 to 0.96). A metabolic signature of 83 metabolites was identified, significantly linked to healthier lifestyles and independently associated with lower BPH risk (HR=0.78, 95% CI: 0.72 to 0.83). Mediation analysis indicated that 19.7% (95% CI: 13.7% to 29.6%) of the lifestyle-BPH risk association was mediated by this signature, mainly through lipoprotein particles, cholesteryl esters in high-density lipoprotein, and phosphatidylcholines. In conclusion, healthy-lifestyle related metabolites were associated with a reduced risk of BPH. The findings highlight the potential of using metabolic signatures as biomarkers for personalized health strategies to reduce BPH incidence. Future research should aim to validate these results across diverse populations and investigate the long-term dynamics of lifestyle-induced metabolic changes.
- Open Access
- 26 September 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04228
Phenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: results from a large-scale longitudinal cohort study
Leukocyte telomere length (LTL) plays a crucial role in human biology, especially for preserving genomic integrity and shielding chromosomal ends from degradation [1]. Telomeres are repeated nucleotide sequences at the ends of chromosomes, and they progressively shorten with each cell division [2]. This process of shortening acts as a biological clock, signalling the age of […]
- 26 September 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04228
Open AccessPhenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: results from a large-scale longitudinal cohort study
Leukocyte telomere length (LTL) plays a crucial role in human biology, especially for preserving genomic integrity and shielding chromosomal ends from degradation [1]. Telomeres are repeated nucleotide sequences at the ends of chromosomes, and they progressively shorten with each cell division [2]. This process of shortening acts as a biological clock, signalling the age of […]
- Open Access
Roles of reactive oxygen species in inflammation and cancer
Reactive oxygen species (ROS) constitute a spectrum of oxygenic metabolites crucial in modulating pathological organism functions. Disruptions in ROS equilibrium span various diseases, and current insights suggest a dual role for ROS in tumorigenesis and the immune response within cancer. This review rigorously examines ROS production and its role in normal cells, elucidating the subsequent regulatory network in inflammation and cancer. Comprehensive synthesis details the documented impacts of ROS on diverse immune cells. Exploring the intricate relationship between ROS and cancer immunity, we highlight its influence on existing immunotherapies, including immune checkpoint blockade, chimeric antigen receptors, and cancer vaccines. Additionally, we underscore the promising prospects of utilizing ROS and targeting ROS modulators as novel immunotherapeutic interventions for cancer. This review discusses the complex interplay between ROS, inflammation, and tumorigenesis, emphasizing the multifaceted functions of ROS in both physiological and pathological conditions. It also underscores the potential implications of ROS in cancer immunotherapy and suggests future research directions, including the development of targeted therapies and precision oncology approaches. In summary, this review emphasizes the significance of understanding ROS‐mediated mechanisms for advancing cancer therapy and developing personalized treatments.
Open AccessRoles of reactive oxygen species in inflammation and cancer
Reactive oxygen species (ROS) constitute a spectrum of oxygenic metabolites crucial in modulating pathological organism functions. Disruptions in ROS equilibrium span various diseases, and current insights suggest a dual role for ROS in tumorigenesis and the immune response within cancer. This review rigorously examines ROS production and its role in normal cells, elucidating the subsequent regulatory network in inflammation and cancer. Comprehensive synthesis details the documented impacts of ROS on diverse immune cells. Exploring the intricate relationship between ROS and cancer immunity, we highlight its influence on existing immunotherapies, including immune checkpoint blockade, chimeric antigen receptors, and cancer vaccines. Additionally, we underscore the promising prospects of utilizing ROS and targeting ROS modulators as novel immunotherapeutic interventions for cancer. This review discusses the complex interplay between ROS, inflammation, and tumorigenesis, emphasizing the multifaceted functions of ROS in both physiological and pathological conditions. It also underscores the potential implications of ROS in cancer immunotherapy and suggests future research directions, including the development of targeted therapies and precision oncology approaches. In summary, this review emphasizes the significance of understanding ROS‐mediated mechanisms for advancing cancer therapy and developing personalized treatments.
- Open Access
- 8 June 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (11) , 4760-4761
The identification of cancer-associated fibroblasts signature for prognosis and drug response in renal papillary cell carcinoma
- 8 June 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (11) , 4760-4761
Open AccessThe identification of cancer-associated fibroblasts signature for prognosis and drug response in renal papillary cell carcinoma